Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

July 29, 2015 6:53 PM ET


Company Overview of Sigma Tau Pharmasource, Inc.

Company Overview

Sigma Tau Pharmasource, Inc., a biopharmaceutical contract manufacturer, offers injectable formulations. It provides tangential flow filtration and high pressure extrusion services, as well as dual chamber vials. Sigma Tau Pharmasource also offers CYSTARAN (cysteamine ophthalmic solution), a topical ophthalmic therapeutic for the treatment of patients suffering from corneal cystine crystal accumulation as a result of cystinosis. The company was formerly known as Klee Pharmaceuticals Inc. and changed its name to Sigma Tau Pharmasource, Inc. in February 2010. Sigma Tau Pharmasource, Inc. was incorporated in 2009 and is based in Indianapolis, Indiana.

6925 Guion Road

Indianapolis, IN 46268

United States

Founded in 2009





Key Executives for Sigma Tau Pharmasource, Inc.

Age: 72
Vice President of Commercial Operations
Compensation as of Fiscal Year 2015.

Sigma Tau Pharmasource, Inc. Key Developments

Sigma-Tau Pharmaceuticals, Inc. Announces First Patient Dosed in Phase I/II Clinical Trial of STP206

Sigma-Tau Pharmaceuticals, Inc. announced that the first patient has been dosed as part of the company's Phase I/II multi center, double blind, randomized, placebo controlled clinical trial for STP206, in development for the prevention of necrotizing enterocolitis (NEC) in very low birth weight premature infants. STP206 is a live biotherapeutic being developed in the United States, under an FDA investigational new drug application (IND). NEC is the most common serious acquired disease of the gastrointestinal tract in preterm infants, most often affecting infants under 1,500 g (3 lbs, 5 oz). The disease is characterized by signs of abdominal distension, intra-abdominal inflammation, and radiologic presence of pneumatosis intestinalis and/or portal venous air or free air indicating perforation of the bowel, which in the most severe cases, can be life threatening. The disease has been reported to occur in approximately 10% of very low birth weight (<=1500 g) infants and about 1 in every 2,000-4,000 births. There is presently no FDA approved treatment for NEC, resulting in an urgent, unmet medical need.

Sigma Tau Pharmasource, Inc. to Supply Pulmaquin to Aradigm Corporation

Sigma-Tau PharmaSource Inc. announced the launch of a broad manufacturing services agreement to provide clinical and commercial supplies of Pulmaquin to Aradigm Corporation. As part of the agreement, Sigma-Tau PharmaSource will manufacture all product for Aradigm's Phase 3 clinical studies, and will support Aradigm in the preparation of its submissions to regulatory authorities in pursuit of marketing approval for the product.

Similar Private Companies By Industry

Company Name Region
Solstice Holdings Inc. United States
SinoFresh Healthcare Products, Inc. United States
Sirga Advanced Biopharma, Inc. United States
ZARS Pharma, Inc. United States
Gebauer Company Inc United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Sigma Tau Pharmasource, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at